Therapeutics: Phosphoinositide 3-kinase α (PI3Kα); phosphoinositide 3-kinase catalytic subunit α polypeptide (PI3KCA; p110α); mammalian target of rapamycin (mTO


Cancer

INDICATION: Cancer

Patient sample and mouse studies suggest inhibiting the PI3Kα/mTOR pathway could help treat venous malformations. Genetic sequencing identified activating mutations in PI3KCA in venous malformation lesions from

Read the full 296 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE